Developer docs
API playgroundTry for free, no card

Search company profiles

Prometheus Life Technologies

Full company profile

uuid0003zkn

Namestring
Prometheus Life Technologies
Legal namestring
Prometheus Life Technologies
Websiteurl
plt.bio
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Prometheus Life Technologies is a Swiss private biotech company that produces human tissue organoids in Low Earth Orbit using microgravity. The company develops a biotechnological process to produce three-dimensional organoids from autologous mesenchymal stem cells in a force-free environment, eliminating the additives and supportive structures required in Earth-based organoid production. Prometheus claims to have established the first full production process for human tissue in microgravity, validated through two ISS missions (SpX-20 and SpX-23) between 2019 and 2021, achieving 100% yield across cartilage, bone, liver, and neuronal tissues with 30+ days of post-flight quality retention.

The company is also developing the first commercial-scale custom hardware for organoid production in microgravity as part of its manufacturing process. Its product portfolio currently centers on organoids for pharmaceutical research, drug testing, precision medicine, and potential transplantation-based therapies, with applications in reducing animal testing.

Prometheus operates a B2B model targeting pharmaceutical companies as the primary segment and life sciences research institutions as a secondary segment. Distribution is via direct enterprise sales, with pricing undisclosed and quote-based. The company is headquartered in Dübendorf, Switzerland, with a European R&D and commercial liaison office in Strasbourg, France, and operates with a small team (1-10 employees) rooted in the University of Zurich research ecosystem. Revenue has not been disclosed, and the company appears to be in pre-commercial stage with its commercial-scale hardware still under development.

Short descriptiontext

Prometheus Life Technologies produces human tissue organoids in Low Earth Orbit using microgravity, serving pharmaceutical companies and life sciences research institutions with higher-quality 3D tissue models for drug testing and regenerative medicine applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersZurich, Switzerland
HQ citystring
Zurich
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microgravity organoids, space biomanufacturing, tissue engineering, drug testing models, regenerative medicine
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Space-based tissue engineering and biomanufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Organoid Product Sales
TypeHardware Sales
Description

Sale of high-quality human tissue organoids produced in microgravity to pharmaceutical companies for drug testing and research purposes, and to life sciences researchers for various applications including precision medicine and transplantation-based therapies.

plt.bio
2Research Partnership Services
TypeProfessional Services
Description

Collaborative research services leveraging the company's microgravity production capabilities and expertise in gravitational biology for pharmaceutical development and testing.

plt.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Prometheus Life Technologies produces human tissue organoids (cartilage, bone, liver, neuronal) in Low Earth Orbit using a proprietary microgravity biotechnological process applied to autologous mesenchymal stem cells, enabling 3D growth and differentiation without the additives or supportive structures required on Earth. The company is also developing the first commercial-scale custom hardware for organoid production in microgravity, and offers collaborative research services for pharmaceutical development and testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% yield achieved for cartilage, bone, liver, and neuronal tissue production in microgravity
+1 more record
Product overview1 text field

Prometheus Life Technologies offers a unified platform centered on space-based organoid production. The core product is human tissue organoids manufactured in Low Earth Orbit using a proprietary microgravity process, which enables superior 3D tissue growth compared to Earth-based production. As part of this offering, the company is developing custom commercial-scale hardware for organoid production in microgravity. The organoids serve pharmaceutical research, drug testing, precision medicine, and potential transplantation therapies.

Product and service3 records
1Organoids
CategorySpace-produced human tissue organoids
Description

Human tissue organoids (cartilage, bone, liver, neuronal) produced in Low Earth Orbit using a proprietary microgravity biotechnological process from autologous mesenchymal stem cells, delivering higher-quality 3D in vitro culture systems for pharmaceutical companies, life sciences researchers, precision medicine, and transplantation-based therapy development.

2Custom Hardware for Organoid Production in Microgravity
CategorySpace biomanufacturing hardware
Description

First commercial-scale custom hardware designed for organoid production in microgravity, built as part of Prometheus's biotechnological production process to enable scalable manufacturing of human tissue organoids in space.

3Research Partnership Services
CategoryResearch and development services
Description

Collaborative research services leveraging Prometheus's microgravity organoid production capabilities and gravitational biology expertise for pharmaceutical development, testing, and life sciences research customers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

European Space Agency Business Incubation Center in Switzerland accepted Prometheus Life Technologies into its startup cohort starting January 2023. Provides business incubation support and access to ESA resources and network.

2Orbital Reef Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

Prometheus won the Reef Starter Innovation Challenge organized by Orbital Reef consortium, which is developing commercial space stations in low Earth orbit. The partnership provides access to Orbital Reef's commercial space station development network and validation opportunities.

plt.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Prometheus Life Technologies originated from the '3D Organoids from Space' project (3DOiS) initiated in 2018 when UZH and Airbus participated in an innovation competition. The company is licensing technology developed at UZH Space Hub. Co-founders Cora Thiel and Oliver Ullrich are associated with UZH Space Hub, with Cora Thiel serving as Chief Scientist Gravitational Biology and Oliver Ullrich as Director of UZH Space Hub.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Airbus participated with University of Zurich in the 2018 innovation competition where the '3D Organoids from Space' project prevailed against roughly 500 other ideas. Airbus involvement in the R&D phase 2019-2021.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

InSphero provides 3D organoid and spheroid-based in vitro models for pharma drug testing and safety assessment, including liver, pancreatic, and cardiac models — directly comparable product offering to Prometheus's organoid portfolio, produced on Earth rather than in microgravity.

2Organoid Therapeutics
TypeEmerging player
Description

Organoid Therapeutics develops patient-derived organoid platforms for drug screening and precision oncology — a niche direct competitor in the pharma organoid space, though focused on cancer applications and Earth-based production.

TypeBroad incumbent
Description

Recursion applies high-throughput biology, imaging, and AI to phenotypic drug discovery at scale — a large, well-capitalized player in AI-enabled drug discovery that competes for pharma R&D budgets, though via phenotypic screening rather than organoid platforms.

TypeBroad incumbent
Description

BICO/Cellink is a broad bioconvergence company offering bioprinters, organoids, and lab automation across pharma and research, overlapping with Prometheus in 3D tissue production and bioprinting but serving customers primarily with Earth-based workflows.

TypeDirect peer
Description

MIMETAS develops organ-on-chip technology (OrganoPlate) for disease modeling and drug screening, serving the same pharma R&D customers as Prometheus with microfluidic 3D tissue models that compete on standardization and human-relevance.

TypeDirect peer
Description

Emulate is a leading organ-on-chip company commercializing human-relevant in vitro models (liver, intestine, lung, brain) for pharma drug testing — directly competing with Prometheus in the pharma-organoid and microphysiological systems space, but with Earth-based chip technology rather than microgravity production.

TypeEmerging player
Description

bit.bio uses proprietary iPSC reprogramming (opti-ox) to produce consistent human cell types at scale for drug discovery and cell therapy — adjacent to Prometheus's organoid platform, focused on iPSC-derived cells rather than microgravity-produced 3D tissues.

8CN Bio
TypeDirect peer
Description

CN Bio develops organ-on-chip platforms (Liver-Chip, Lung-Chip) used by pharma for drug discovery and toxicology, addressing the same human-relevant testing pain points Prometheus targets, but via single- and multi-organ microphysiological systems on Earth.

9Aspect Biosystems
TypeEmerging player
Description

Aspect Biosystems develops 3D bioprinted tissue therapeutics and in vitro tissue models using microfluidic bioprinting technology — overlapping with Prometheus in biofabrication and 3D tissue production for pharma, though focused on implantable therapeutics.

TypeRegional player
Description

SpacePharma provides microgravity R&D services and miniaturized lab hardware for in-orbit experiments, including cell culture and biological research — adjacent to Prometheus as a space-life-science infrastructure provider rather than a direct organoid product competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prometheus Life Technologies

Space-based tissue engineering and biomanufacturingplt.bio

Prometheus Life Technologies produces human tissue organoids in Low Earth Orbit using microgravity, serving pharmaceutical companies and life sciences research institutions with higher-quality 3D tissue models for drug testing and regenerative medicine applications.

What Prometheus Life Technologies does

Prometheus Life Technologies is a Swiss private biotech company that produces human tissue organoids in Low Earth Orbit using microgravity. The company develops a biotechnological process to produce three-dimensional organoids from autologous mesenchymal stem cells in a force-free environment, eliminating the additives and supportive structures required in Earth-based organoid production. Prometheus claims to have established the first full production process for human tissue in microgravity, validated through two ISS missions (SpX-20 and SpX-23) between 2019 and 2021, achieving 100% yield across cartilage, bone, liver, and neuronal tissues with 30+ days of post-flight quality retention.

The company is also developing the first commercial-scale custom hardware for organoid production in microgravity as part of its manufacturing process. Its product portfolio currently centers on organoids for pharmaceutical research, drug testing, precision medicine, and potential transplantation-based therapies, with applications in reducing animal testing.

Prometheus operates a B2B model targeting pharmaceutical companies as the primary segment and life sciences research institutions as a secondary segment. Distribution is via direct enterprise sales, with pricing undisclosed and quote-based. The company is headquartered in Dübendorf, Switzerland, with a European R&D and commercial liaison office in Strasbourg, France, and operates with a small team (1-10 employees) rooted in the University of Zurich research ecosystem. Revenue has not been disclosed, and the company appears to be in pre-commercial stage with its commercial-scale hardware still under development.

Prometheus Life Technologies firmographics

Firmographics
Name
Prometheus Life Technologies
Legal name
Prometheus Life Technologies
Website
https://plt.bio
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Prometheus Life Technologies produces human tissue organoids in Low Earth Orbit using microgravity, serving pharmaceutical companies and life sciences research institutions with higher-quality 3D tissue models for drug testing and regenerative medicine applications.
Ownership category
akta.pro rank

Prometheus Life Technologies industry classification

Industry
Product category
Space-based tissue engineering and biomanufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Microgravity organoids
  • Space biomanufacturing
  • Tissue engineering
  • Drug testing models
  • Regenerative medicine

Where Prometheus Life Technologies is headquartered

Location

Headquarters

HQ city
Zurich
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Prometheus Life Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Organoid Product Sales: Sale of high-quality human tissue organoids produced in microgravity to pharmaceutical companies for drug testing and research purposes, and to life sciences researchers for various applications including precision medicine and transplantation-based therapies.
  2. Research Partnership Services: Collaborative research services leveraging the company's microgravity production capabilities and expertise in gravitational biology for pharmaceutical development and testing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Prometheus Life Technologies product offering

Product offering

Core offering

Prometheus Life Technologies produces human tissue organoids (cartilage, bone, liver, neuronal) in Low Earth Orbit using a proprietary microgravity biotechnological process applied to autologous mesenchymal stem cells, enabling 3D growth and differentiation without the additives or supportive structures required on Earth. The company is also developing the first commercial-scale custom hardware for organoid production in microgravity, and offers collaborative research services for pharmaceutical development and testing.

Product overview

Prometheus Life Technologies offers a unified platform centered on space-based organoid production. The core product is human tissue organoids manufactured in Low Earth Orbit using a proprietary microgravity process, which enables superior 3D tissue growth compared to Earth-based production. As part of this offering, the company is developing custom commercial-scale hardware for organoid production in microgravity. The organoids serve pharmaceutical research, drug testing, precision medicine, and potential transplantation therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Organoids Human tissue organoids (cartilage, bone, liver, neuronal) produced in Low Earth Orbit using a proprietary microgravity biotechnological process from autologous mesenchymal stem cells, delivering higher-quality 3D in vitro culture systems for pharmaceutical companies, life sciences researchers, precision medicine, and transplantation-based therapy development.
  • Custom Hardware for Organoid Production in Microgravity First commercial-scale custom hardware designed for organoid production in microgravity, built as part of Prometheus's biotechnological production process to enable scalable manufacturing of human tissue organoids in space.
  • Research Partnership Services Collaborative research services leveraging Prometheus's microgravity organoid production capabilities and gravitational biology expertise for pharmaceutical development, testing, and life sciences research customers.

Quantifiable outcome

  • 100% yield achieved for cartilage, bone, liver, and neuronal tissue production in microgravity
  • +1 more outcomes

Companies that use Prometheus Life Technologies

Customer profile

Segments2 records

Ideal customer profiles2 records

Prometheus Life Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Prometheus Life Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • ESA-BIC SwitzerlandcoreStrategic or Co-development Partner · 1 January 2023European Space Agency Business Incubation Center in Switzerland accepted Prometheus Life Technologies into its startup cohort starting January 2023. Provides business incubation support and access to ESA resources and network.
  • Orbital Reef ConsortiumminorStrategic or Co-development Partner · 1 December 2022Prometheus won the Reef Starter Innovation Challenge organized by Orbital Reef consortium, which is developing commercial space stations in low Earth orbit. The partnership provides access to Orbital Reef's commercial space station development network and validation opportunities.
  • University of Zurich / UZH Space HubcoreStrategic or Co-development Partner · 1 January 2018Prometheus Life Technologies originated from the '3D Organoids from Space' project (3DOiS) initiated in 2018 when UZH and Airbus participated in an innovation competition. The company is licensing technology developed at UZH Space Hub. Co-founders Cora Thiel and Oliver Ullrich are associated with UZH Space Hub, with Cora Thiel serving as Chief Scientist Gravitational Biology and Oliver Ullrich as Director of UZH Space Hub.
  • AirbusminorStrategic or Co-development Partner · 1 January 2018Airbus participated with University of Zurich in the 2018 innovation competition where the '3D Organoids from Space' project prevailed against roughly 500 other ideas. Airbus involvement in the R&D phase 2019-2021.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Prometheus Life Technologies competitors and assessment

Company assessment

Direct peers

  • InSphero: InSphero provides 3D organoid and spheroid-based in vitro models for pharma drug testing and safety assessment, including liver, pancreatic, and cardiac models — directly comparable product offering to Prometheus's organoid portfolio, produced on Earth rather than in microgravity.
  • MIMETAS: MIMETAS develops organ-on-chip technology (OrganoPlate) for disease modeling and drug screening, serving the same pharma R&D customers as Prometheus with microfluidic 3D tissue models that compete on standardization and human-relevance.
  • Emulate Bio: Emulate is a leading organ-on-chip company commercializing human-relevant in vitro models (liver, intestine, lung, brain) for pharma drug testing — directly competing with Prometheus in the pharma-organoid and microphysiological systems space, but with Earth-based chip technology rather than microgravity production.
  • CN Bio: CN Bio develops organ-on-chip platforms (Liver-Chip, Lung-Chip) used by pharma for drug discovery and toxicology, addressing the same human-relevant testing pain points Prometheus targets, but via single- and multi-organ microphysiological systems on Earth.

Emerging players

  • Organoid Therapeutics: Organoid Therapeutics develops patient-derived organoid platforms for drug screening and precision oncology — a niche direct competitor in the pharma organoid space, though focused on cancer applications and Earth-based production.
  • bit.bio: bit.bio uses proprietary iPSC reprogramming (opti-ox) to produce consistent human cell types at scale for drug discovery and cell therapy — adjacent to Prometheus's organoid platform, focused on iPSC-derived cells rather than microgravity-produced 3D tissues.
  • Aspect Biosystems: Aspect Biosystems develops 3D bioprinted tissue therapeutics and in vitro tissue models using microfluidic bioprinting technology — overlapping with Prometheus in biofabrication and 3D tissue production for pharma, though focused on implantable therapeutics.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion applies high-throughput biology, imaging, and AI to phenotypic drug discovery at scale — a large, well-capitalized player in AI-enabled drug discovery that competes for pharma R&D budgets, though via phenotypic screening rather than organoid platforms.
  • Cellink (BICO): BICO/Cellink is a broad bioconvergence company offering bioprinters, organoids, and lab automation across pharma and research, overlapping with Prometheus in 3D tissue production and bioprinting but serving customers primarily with Earth-based workflows.

Regional players

  • SpacePharma: SpacePharma provides microgravity R&D services and miniaturized lab hardware for in-orbit experiments, including cell culture and biological research — adjacent to Prometheus as a space-life-science infrastructure provider rather than a direct organoid product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Prometheus Life Technologies social profiles

Digital presence

Prometheus Life Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prometheus Life Technologies leadership team

Management profile

Number of profiles

Profiles8 records

Prometheus Life Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prometheus Life Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prometheus Life Technologies

What does Prometheus Life Technologies do?

Prometheus Life Technologies produces human tissue organoids (cartilage, bone, liver, neuronal) in Low Earth Orbit using a proprietary microgravity biotechnological process applied to autologous mesenchymal stem cells, enabling 3D growth and differentiation without the additives or supportive structures required on Earth. The company is also developing the first commercial-scale custom hardware for organoid production in microgravity, and offers collaborative research services for pharmaceutical development and testing.

Is Prometheus Life Technologies a public or private company?

Prometheus Life Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prometheus Life Technologies founded?

Prometheus Life Technologies was founded in 2018. It employs 1 to 10 people.

Where is Prometheus Life Technologies based?

Prometheus Life Technologies is headquartered in Zurich, Switzerland, in the Europe region.

How does Prometheus Life Technologies make money?

Two revenue lines are on record. Organoid Product Sales are the primary driver. The others are research Partnership Services.

Who are Prometheus Life Technologies's main competitors?

Direct peers on record are InSphero, MIMETAS, Emulate Bio and CN Bio. Emerging players are Organoid Therapeutics, bit.bio and Aspect Biosystems. Broad incumbents are Recursion Pharmaceuticals and Cellink (BICO). SpacePharma is listed as a regional player.

Does Prometheus Life Technologies have an API?

No public API is recorded for Prometheus Life Technologies.

What industry is Prometheus Life Technologies in?

Prometheus Life Technologies's product category is Space-based tissue engineering and biomanufacturing. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales